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Objectives: Numbers of newly diagnosed HIV infections among men who have sex with men (MSM) in 
Germany increased after the year 2000. We sought to explore trends in STI co-infections around the 
time of HIV seroconversion in patients from the German HIV-1 seroconverter cohort from 1996-2007. 
Methods: MSM from the cohort were included forsecondary analysis, if seroconversion occurred 
between 1996 and 2007 and if a blood sample taken within 2 y after HIV infection was available for 
further testing. Samples were tested for antibodies against Treponema pallidum and HSV-2. A 
classification system was developed to assign the chronology of syphilis and HIV-1 infection. 
Results: Data of 1052 MSM were eligible for analysis. Overall seroprevalence of syphilis markers was 
26%, increasing from 10% (1996-1999) to 35% (2005). Among HIV seroconverters with positive 
syphilis antibodies, 32% (n=88) were rated as having had coincident infections with HIV and syphilis. 
Coincident syphilis infection at HIV diagnosis increased substantially (p<0.001) from 2.3% in 2000 to 
16.9% in 2003; and thereafter declined to 4.3% in 2007. Mean HSV-2 antibody prevalence was 
40.5%, mean anti-HSV-2 IgM prevalence was 11.2%, with no significant change over time. 
Discussion: We found a stable prevalence of HSV-2 infection and increasing prevalence of syphilis 
infection around the time of HIV acquisition among MSM in Germany. Time course and rate of co-
infections suggest that a re-emerging syphilis co-epidemic among MSM after 2000 could have 





Epidemiological data show an increase in newly diagnosed HIV infections among men who have sex 
with men (MSM) in Germany as well as other countries in Western Europe, North America and 
Australia after the year 2000.1 Simultaneously, increasing syphilis prevalence and incidence have 
been identified in the same subpopulation group.2 In Germany, the number of newly reported syphilis 
cases more than doubled since 2001 and reached mean values of approximately 4/1000 MSM in 
2004 and the following years.3 4  
 
It has been hypothesised that a rise in infections with HIV can be caused by an increase of the per-
contact probability for HIV transmission due to ulcerative sexually transmitted infections (STIs) like 
syphilis and anogenital herpes.5 In this report, we sought to explore trends in coincident HIV, syphilis 
and herpes simplex virus 2 (HSV-2) infection in HIV patients from the German HIV-1 seroconverter 










The German HIV-1 Seroconverter Study is a national prospective multi-centre observational cohort 
that started in 1997. The study was approved by the ethics committee of the Charité University Clinic 
in Berlin. The study design has been described in detail elsewhere.6 In brief, as of 31 December 2007, 
a total of 1285 blood samples of HIV-1 seroconverters were available for screening for syphilis, HSV-1 
and HSV-2 co-infection. The first blood sample taken after enrollment was used for analysis if the 
blood sample was taken within 2 y after the estimated date of HIV seroconversion. The serological 
tests for syphilis, HSV-1 and HSV-2 were performed with frozen plasma samples, including 
ARCHITECT Syphilis TP chemiluminescence microparticle immunoassay (Abbott, Wiesbaden, 
Germany) for screening and fluorescent treponemal antibody absorption (FTAABS) test for 
confirmation, and the Treponema pallidum particle agglutination (TPPA) assay for the determination of 
treponemal antibody titres in reactive samples. The presence of HSV-1, HSV-2 IgG and HSV-2 IgM 
antibodies in the samples were tested using ELISA test kits for the quantitative determination of type-
specific antibodies against the glycoproteins G-1 (HSV-1) and G-2 (HSV-2).  
 
For the assessment of syphilis disease activity in reactive samples, two additional tests were 
performed: as a lipoidal antibody test a modification of the Venereal Disease Research Laboratory 
(VDRL) test, the RPR reditest (Biokit, Barcelona, Spain) was used. Treponemal IgM antibodies were 
determined quantitatively by the IgM-FTA-ABS test after elimination of the IgG fraction from the 
sample with an anti-IgG serum, using the same antigen and sorbent as for the IgG-FTA-ABS test and 
a rabbit anti-human IgM-FITC conjugate. IgM antibody titres <1:10 were classified as negative, titres of 
1:10 as borderline, titres of 1:20 as weak positive and titres ≥1:40 as positive. Serological testing was 
performed at Labor Krone, Bad Salzuflen, Germany.  
 
Further information on the study subjects were provided by their respective HIV healthcare provider, 
including information on gender and the supposed route of HIV transmission (injecting drug user, 
migrant from a country with high HIV prevalence, heterosexual, MSM, unknown). For the calculation of 
a chronological relation between HIV seroconversion and syphilis infection, analysis was restricted to 
male subjects reported to be MSM or with unknown route of HIV transmission (MSM/u).  
 
Based on (i) antibody patterns for syphilis, (ii) the time interval between blood sampling and estimated 
date of HIV infection and (iii) information about a history of syphilis within the previous 2 y (yes/ no), 
provided by the study subjects’ HIV healthcare facility, HIV seroconverters were assigned to the 
following three groups: (1) active syphilis predated HIV seroconversion, (2) active syphilis coincident 
with HIV seroconversion and (3) syphilis acquired after HIV seroconversion. If a history of syphilis was 
reported, we assumed that adequate antibiotic treatment had been provided.  
 
If the blood sample was taken within 3 months after the estimated time point of HIV infection, groups 
were defined as follows: 
Group 1: IgM titre <1:40 and VDRL titre <1:8 
Group 2: IgM titre ≥1:40 or VDRL titre ≥1:8 
Group 3: not applicable. 
 
If the blood sample was taken between 4 and 24 months after the estimated time of HIV infection, 
groups were defined as follows: 
Group 1: IgM titre <1:10 and VDRL titre <1:2 
Group 2: IgM titre >1:10 or VDRL titre >1:2 and not meeting 
definition for group 3 
Group 3: IgM titre ≥1:80 if blood sample was taken between 12 and 24 months after infection, IgM titre 
≥1:320 if sample was taken within 7-12 months after infection, IgM titre ≥1:1280 if sample was taken 
within 4-6 months after infection.  
 
Seroconverters with IgM titre=1:10 or VDRL titre=1:2 were individually grouped based on information 
about history of syphilis in the previous 2 y.  
Group 1: no history of syphilis within the previous 2 y  
Group 2: history of syphilis within the previous 2 y. 
 
To evaluate potential confounders for the observed trends on HIV syphilis co-infection, we analysed 
time trends in the study sample of HIV-1 seroconverters for the following parameters: As surrogate 
markers for ‘recruitment bias’: age at HIV infection and proportion of HIV seroconverters recruited in 
  
Berlin (largest city in Germany); as markers of a ‘group assignation bias’: ratio of documented (last 
negative/ first positive HIV test result) versus acute (according to laboratory criteria: i) detectable HIV-1 
RNA or p24 antigen combined with a negative or indeterminate ELISA result or ii) reactive HIV-1-
ELISA combined with a negative or indeterminate immunoblot result followed by confirmation of 
complete seroconversion within 6 months) HIV seroconversion; mean time between last negative and 
first positive HIV test result; mean time between calculated date of infection and first available blood 
sample; as an indicator for changes in sexual risk behaviour: proportion of seroconverters with HSV-1 
and HSV-2 antibodies and with HSV-2 IgM antibodies (it has been shown that incident infection with 
HSV-2 in MSM is significantly associated with a variety of anal sex practices with casual partners).7  
 
We used a log-linear regression model (Poisson regression8) to detect trends in the syphilis co-
infection rate in the group of MSM/u seroconverters. We investigated coincident and preceding 
episodes of syphilis separately and checked whether other variables had a significant influence. 





Of 1285 HIV-1 seroconverters included in the cohort, 1105 were reported as MSM/u, among these 
1052 had a blood sample taken within 2 y after the estimated date of HIV infection. In total, 276 
MSM/u (26.2%) were positive for treponemal antibodies (TPPA), the median distance to the estimated 
time point of HIV infection was 5 months. A single subject could not be assigned to one of the three 
groups as described above. Out of the remaining 275 MSM/u (MSM=270; unknown risk=5), 88 
(31.9%) were assigned to the group with coinciding infections with HIV and syphilis (group 2), 176 
men (63.8%) to the group with treponemal infection preceding HIV infection (group 1) and 11 men to 
the group where HIV infection was followed by syphilis infection (group 3; see figure 1).  
 
The overall proportion of syphilis seromarkers among MSM/u HIV seroconverters significantly 
increased (p<0.001) from 9.8% (1996-1999) to 34.7% (2005) and thereafter declined to 23.4% (2007). 
The proportion of men with syphilis infection preceding HIV infection (group 1) increased from 6.1% 
(1996-1999) to 22.7% (2004) (p<0.001) and thereafter slightly declined to 19.1% (2007).  
 
Coincident syphilis infection at HIV seroconversion (group 2) increased from 2.3% (1996-1999) to 
16.9% (2003) (p<0.001) and thereafter declined to 4.3% (2007) (see table 1 and figure 2).  
 
The mean age at HIV infection increased from 32 to 35 y over the observation period. The proportion 
of seroconverters recruited in Berlin, the city with the largest gay population in Germany, remained 
stable around 70%. The proportion of documented to acute HIV seroconversion and the mean time 
interval between HIV infection and blood sample declined stepwise over time. In all seroconverters, 
time between last negative and first positive test result did not change significantly during the 
observation period. The proportion of seroconverters with antibodies against HSV-1 fluctuated around 
90%, the proportion with HSV-2 antibodies around 40%, with no clear trends over time. The same was 
observed regarding the proportion with HSV-2 IgM antibodies (prevalence between 7 and 16%; see 
table 1).  
 
Analysing time trends by Poisson regression, we found a significant increase of coincident syphilis 
infections in MSM/useroconverters in the time period from 1996 up to 2003: on average the incidence 
rate increased by 51.8% (95% CI 20.6% to 91.1%) per year. Other variables showed no significant 
influence on the incidence of coincident syphilis.  
 
For syphilis preceding HIV infection we found a significant increase between 1996 and 2004. 
Moreover, in a multivariate model we found in the same period an additional influence of age at 
seroconversion and place of residence. On average, the syphilis antibody prevalence rate increased 
by 19.0% (95% CI 6.6% to 32.8%) per year; for each year of age the prevalence of a preceding 
syphilis infection increased by 2.9% (95% CI 0.4% to 5.5%); seroconverters from Berlin had a 84.9% 









We found a significant increase in the prevalence of syphilis antibodies in MSM HIV-seroconverters 
between 2000 and 2005. During this period, the number of reported syphilis cases in Germany more 
than doubled. A more detailed analysis of syphilis antibody patterns suggested that a large proportion 
(~2/3) of these syphilis antibody positive HIV seroconverters may have acquired syphilis before HIV, 
but also the proportion of probably coincident HIV and syphilis infections increased significantly from 
before 2000 to 2003 with levelling off and decline thereafter. Interestingly, in contrast to increasing 
prevalence of syphilis antibodies in HIV seroconverters, we did not find any consistent changes for 
HSV-2 antibody prevalence. The presence of HSV-1 antibody was almost universal (~90%). 
Prevalence of HSV-1 and HSV-2 antibodies was comparable to reports about HIV-positive MSM from 
the Netherlands and the United Kingdom.9 10  
 
We were able to analyse time trends for only a limited set of other parameters in the seroconverter 
cohort. We observed a slightly increasing trend for age at HIV seroconversion (reflected as well in the 
national surveillance data for HIV and syphilis in MSM), a trend for improved recognition of acute 
seroconversion (declining ratio of documented/ acute seroconversion) and faster recruitment of 
seroconverters into the cohort (declining time delay between seroconversion and blood sample) over 
time. Data outliers in 2007 for both of these parameters are likely due to a cohort effect (over-
representation of acute seroconversions with shorter time between seroconversion and recruitment 
into the cohort). For HIV seroconverters classified as having had syphilis before HIV infection we 
found a statistically significant association with age and place of residence for the time period until 
2004-a finding reflecting the time-space evolution of the syphilis co-epidemic in MSM in Germany. This 
association with age and residence was not detected for HIV seroconverters classified as coincident 
syphilis/HIV infection. Otherwise, we could find no indication for any significant interaction of other 
identified time trends on the time trends for HIV-syphilis co-infection.  
 
Syphilis circulation in the MSM population in Western Europe and North America reached a historic 
nadir during the 1990s. HSV-2, although declining in HIV-negative MSM as well, remained prevalent at 
high levels in HIV-positive men.9 Epidemiological dynamics for these two STIs are quite different: 
syphilis usually becomes symptomatic, can be cured by antibiotics and remains infectious only for a 
limited time period even without treatment. HSV-2 can only be suppresseddnot cureddby antiviral 
drugs and it establishes a persistent infection with recurrent viral shedding. Due to these differences, 
maintaining endemic levels of syphilis circulation requires a certain degree of delayed diagnosis and 
core groups with high partner numbersdat least in countries with free access to healthcare, diagnosis 
and treatment.  
 
The reasons for the re-emergence of syphilis in MSM populations in the last decade are not fully 
understood. Observations in Germany argue for the re-establishment of an endemic level of syphilis 
circulation in a population in which the infectious agent transiently almost had disappeared.11 The 
transient disappearance may have been at least partly due to the shrinking of a core group that 
maintains uninterrupted syphilis circulation.12 The re-establishment of this core group after 1996, 
rather than general increases in sexual risk behaviours of HIV negative and untested MSM (eg, 
increase of partner numbers and unprotected anal intercourse), may feed continuous syphilis 
circulation. Once the infectious agentdT pallidumdbecame prevalent in these core groups again, it 
quickly re-established a new level of endemicity (comparable to the pre-AIDS era). In the core groups, 
partner numbers and prevalence of unprotected anal intercourse are high but unprotected sex takes 
place mostly within a context of HIV serosorting.13  
 
Syphilis and HIV surveillance data from Germany demonstrate transient increases in syphilis cases 
and newly diagnosed HIV in MSM levelling off since 2004 (syphilis) and 2007 (HIV) (see supplemental 
online figure 3). An increasing prevalence of syphilis in subpopulations at risk for HIV during this 
period could have resulted in an increase of HIV transmission probability due to effects of coincident 
syphilis on HIV susceptibility and infectivity. If our hypothesis is correct, the increase of HIV incidence 
in MSM should level off as soon as the new endemic level of syphilis circulation is reacheddwith a 
certain time delay due to a longer gap between infection and diagnosis for HIV compared with syphilis.  
 
There are several limitations to our analysis. The analysis of the impact of other STIs on the risk of 
HIV seroconversion was not a primary aim of the HIV Seroconverter Cohort. Therefore, the amount of 
data and information about the participants to investigate this issue is limited and in this respect the 
study suffers from the general drawbacks of a retrospective case-note review. The estimated dates of 
  
HIV infection in those cases in which no acute HIV infection was observed but the date was defined as 
the midpoint between the last negative and the first positive HIV antibody test6 do not necessarily 
represent the actual date of infection.  
 
Our group definitions based on antibody patterns are quite crude since there was no possibility to get 
information on the timing of suspicious clinical manifestations and antibody titres at the time of syphilis 
diagnosis and treatment initiation were not available. Since the duration of infection and the baseline 
titres of syphilis antibodies at treatment initiation determine the time course of their following declines 
there is certainly room for misclassifications. Misclassifications may occur in both directions: falsely 
classifying cases as coincident and falsely classifying cases as syphilis preceding HIV infection. 
Particularly in those patients in which the analysed blood sample was collected more than 3 months 
after the estimated time of HIV infection, IgM and VDRL antibodies may have been eliminated already 
after adequate syphilis treatment even if syphilis coincided with HIV transmission. Hence, we feel that 
our classification system results in a rather conservative estimate of the proportion of coincident 
infections. Accordingly, group 1 with syphilis preceding HIV infection was the largest group.  
 
A comparison of syphilis antibody prevalence in the group of HIV seroconverters presented here with 
a control group of HIV negative sexually active MSM from Berlin tested in 2006 showed a threefold 
higher syphilis seroprevalence in HIV seroconverters in 2006 (29% vs 9%) (unpublished own data). 
These data support the view that coincident infections might be underestimated by the algorithm 
applied here.  
 
Furthermore, the biological basis for the impact of syphilis on an individual’s susceptibility for HIV 
infection has not yet been clearly defined. Besides direct interactions like breaks to the mucosal 
integrity, immunological interactions like increased concentration of potential HIV target cells at the 
portal of entry and increased CCR5 co-receptor expression may play a role. The evolution of these 
immunological factors over time and their dependence and interaction with syphilis treatment has not 
yet been elucidated in detail.14 As demonstrated for HSV-2 infection, the period of hyper-susceptibility 
for HIV infection may extend beyond the active stage of disease.15  
 
One further aspect of syphilis as a HIV transmission co-factor, which is not reflected in this analysis, is 
an enhancing effect of syphilis co-infection in HIV infected individuals that results only in HIV 
transmission but not in syphilis transmission.  
 
Participants of the HIV seroconverter study are primarily recruited in Germany’s largest cities and, 
thus, do not represent HIV seroconverters in smaller cities and rural areas. Hence, our findings may 
not be generalisable to all MSM. However, German surveillance data show that HIVand syphilis 
diagnosis incidence increased coincidentally in all parts of Germany: the rise in syphilis incidence 
occurred first among gay communities in metropolitan areas, where a first peak occurred in 
2003/2004, followed by transient declines (see surveillance data for Berlin, supplemental online figure 
3). However, it could also be observed outside of the largest cities with a time delay of 1 to 2 y.2 In 
nonmetropolitan areas, the increase of newly diagnosed HIV infections in parallel with increasing 
syphilis incidence was even more pronounced.  
 
In summary, we found a considerable overlap of HSV-2 and syphilis infection and HIV acquisition 
among MSM/u in the German HIV Seroconverter Cohort. The time course and rate of co-infections 
suggest that the re-emergence of a syphilis coepidemic among MSM after 2000 could have 
contributed to an increase of HIV incidence. Our data support the hypothesis that the increase of 
newly diagnosed HIV infections in MSM after the year 2000 may at least partly be a result of enhanced 
HIV transmission probability rather than general and widespread changes of HIV-related risk 
behaviours.5 16  
 
At the same time, the high prevalence of previous syphilis episodes before HIV seroconversion argues 
for targeted interventions to strengthen HIV protective behaviour in HIV negative MSM who are 
diagnosed with newly acquired syphilis.  
 
Experiences so far with addressing STI co-factors as a means to reduce HIV incidence have often 
been disappointing.17 However, the high incidence and prevalence of syphilis in definable and 
accessible MSM subpopulations is by itself a reason for concern and should prompt increasing efforts 
to get this epidemic under control. Including syphilis into regular monitoring of HIV infected patients 
and improving sexual healthcare for at risk populations by low threshold sites for HIV/STI- diagnosis 




We wish to acknowledge the careful management of the stored plasma samples done by Sabrina 
Neumann and Hanno von Spreckelsen. Furthermore, we thank Axel J Schmidt for critical review of the 
manuscript. Funding Funding for the German HIV Seroconverter Cohort was granted by the German 
Federal Ministry of Health.  
 
 
Author footnote Participating collaborators of the German HIV-1 Seroconverter Study Group Aachen: 
Drs Habets and Knechten; Augsburg: Dr Hammond (Klinikum Augsburg); Berlin: Drs Mayr, Schmidt, 
Speidel and Strohbach (Medizinisches Versorgungszentrum, Ärzteforum Seestraße), Dr Arastéh 
(Auguste-Viktoria-Krankenhaus/Vivantes), Drs Bieniek and Cordes, Dr Claus, Drs. Baumgarten, 
Carganico and Dupke, Drs Freiwald and Rausch, Drs Gölz, Klausen, Mol, and Schleehauf, Dr 
Hintsche, Drs Jessen and Jessen, Drs Köppe and Krauthausen, Dr Reuter; Bielefeld: Dr Pfaff 
(Krankenhaus MARA II); Bochum: Prof Dr Brockmeyer (St Joseph-Hospital); Bonn: Prof Dr Rockstroh 
(Universitätsklinik Bonn); Dortmund: Prof Dr Gehring and Dr Schmalöer and Dr Hower (Klinikum 
Dortmund, ID27 Ambulanz); Dresden: Prof Dr Spornraft-Ragaller (Universitätsklinikum Dresden); 
Duisburg: Dr Becker-Boost, Dr Kwirant; Düsseldorf: Prof Dr Häussinger and PD Dr Reuter 
(Universitätsklinik Düsseldorf); Frankfurt/Main: Prof Dr Helm (Universitätsklinik Johann-Wolfgang-
Goethe-Universität); Frankfurt/Oder: 
Dr Markus; Halle/Saale: Dr Kreft (Universitätsklinik Martin-Luther-Universität); Hamburg: Prof Dr 
Plettenberg, Dr Stoehr, Dr Graefe and Dr Lorenzen (Institut für Infektionsmedizin, ifi, Allgemeines 
Krankenhaus St. Georg); Drs Adam, Schewe and Weitner, Dr Fenske, Dr. Hansen, Prof Dr Stellbrink 
(Infektionsmedizinisches Zentrum Hamburg, ICH); Hannover: Prof Dr Schmidt (Medizinische 
Hochschule Hannover), Drs Buck and Leugner; Koblenz: Prof Dr Eisenhauer and Dr Rieke 
(Krankenhaus Kemperhof); Köln: Dr Bihari, Dr Ferdinand, Prof Dr Fätkenheuer (Universitätsklinik 
Köln); Prof Dr Oette, Krankenhaus der Augustinerinnen, Köln; Leipzig: Dr Pfeil (Universitätsklinik 
Leipzig); Magdeburg: Prof Dr Malfertheiner and Dr Wolle (Universitätsklinik Otto-v-Guericke-
Universität); Mainz: Prof Dr Galle (Klinikum der Joh-Gutenberg-Universität); München: Drs Jäger and 
Jägel-Guedes, Dr Malm, Dr Rieger, Städtisches Krankenhaus 12 München-Schwabing, Prof Dr 
Fröschl (Technische Universität München); Münster: Prof Dr Rahn (Universitätsklinik Münster); 
Norderstedt: Dr Soldan; Nürnberg: Dr Brockhaus (Klinikum Nürnberg); Osnabrück: Dr Mutz 
(Städtische Klinik Natruper Holz); Regensburg: Prof Dr Salzberger, Prof Dr Schölmerich and Dr 
Schneidewind (Universitätsklinik Regensburg); Remscheid: Dr Steege; Rostock: Dr Kreft, Prof Dr 
Ziegler and Prof Dr Reisinger (Universitätsklinik Rostock); Stuttgart: Drs Ißler, Schaffert, Schnaitmann 
and Trein, Drs Frietsch, Müller and Ulmer; Dr Wagner-Wiening (Landesgesundheitsamt Stuttgart); 




Competing interests None.  
 




Contributors The study was conceived and supervised by UM. NS analysed the data and drafted the 
manuscript. DM and H-JH supervised the antibody testing of the blood samples and participated in the 
development of the classification system for group assignment based on the antibody patterns. MH 
was responsible for the statistical and interaction analyses. CH extracted the relevant data from the 
HIV seroconverter cohort database. BG-B, CK and KK coordinate and supervise the HIV 
seroconverter cohort and the sample collection and testing. OH supervises the HIV seroconverter 
cohort and critically revised the manuscript. All authors contributed to the final manuscript.  
 










1. Sullivan PS, Hamouda O, Delpech V, et al. Reemergence of the HIV epidemic among men who 
have sex with men in North America, Western Europe, and Australia, 1996-2005. Annals of 
epidemiology 2009;19:423e31. 
2. Marcus U, Hamouda O. Syphilis in Germany, 2004: diagnoses increasing, particularly in smaller 
cities and rural areas. Euro Surveill 2005;10:E050728 050723. 
3. Marcus U, Schmidt AJ, Kollan C, et al. The denominator problem: estimating MSMspecific incidence 
of sexually transmitted infections and prevalence of HIV using population sizes of MSM derived from 
Internet surveys. BMC public health 2009;9:181. 
4. Marcus U, Schmidt AJ, Hamouda O, et al. Estimating the regional distribution ofmenwho have sex 
with men (MSM) based on Internet surveys. BMC public health 2009;9:180. 
5. Hoare A, Wilson DP, Regan DG, et al. Using mathematical modelling to help explain the differential 
increase in HIV incidence in New South Wales, Victoria and Queensland: importance of other sexually 
transmissible infections. Sex Health 2008;5:169e87. 
6. Poggensee G, Kücherer C, Werning J, et al. Impact of transmission of drugresistant HIV on the 
course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study. HIV 
Medicine 2007;8:511e19. 
7. Jin F, Prestage GP, Mao L, et al. Transmission of herpes simplex virus types 1 and 2 in a 
prospective cohort of HIV-negative gay men: the health in men study. J Infect Dis 2006;194:561e70.  
8. Frome EL. The analysis of rates using poisson regression models. Biometrics 1983;39:665e74. 
9. Smit C, Pfrommer C, Mindel A, et al. Rise in seroprevalence of herpes simplex virus type 1 among 
highly sexual active homosexual men and an increasing association between herpes simplex virus 
type 2 and HIV over time (1984-2003). Eur J Epidemiol 2007;22:937e44. 
10. Hill C, McKinney E, Lowndes CM, et al. Epidemiology of herpes simplex virus types 2 and 1 
amongst men who have sex with men attending sexual health clinics in England and Wales: 
implications for HIV prevention and management. Euro Surveill 2009;14. 
11. Savage EJ, Hughes G, Ison C, et al. Syphilis and gonorrhoea in men who have sex with men: a 
European overview. Euro Surveill 2009;14:19417. 
12. Chesson HW, Gift TL. Decreases in AIDS mortality and increases in primary and secondary 
syphilis in men who have sex with men in the United States. J Acquir Immune Def Syndr 
2008;47:263e4. 
13. Parsons JT, Schrimshaw EW, Wolitski RJ, et al. Sexual harm reduction practices of HIV-
seropositive gay and bisexual men: serosorting, strategic positioning, and withdrawal before 
ejaculation. AIDS 2005;19:S13e25. 
14. Salazar JC, Cruz AR, Pope CD, et al. Treponema pallidum elicits innate and adaptive cellular 
immune responses in skin and blood during secondary syphilis: a flowcytometric analysis. Journal of 
Infectious Diseases 2007;195:879e87. 
15. Zhu J, Hladik F, Woodward A, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 
reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009;15:886e92. 
16. Marcus U, Kollan C, Bremer V, et al. Relation between the HIV and the re-emerging syphilis 
epidemic among MSM in Germany: an analysis based on anonymous surveillance data. Sexually 
Transmitted Infections 2005;81:456e7. 
17. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected 


















Tables and Figures 
 
 
Figure 1 Flowchart of analysis and group assignments. 
 
 
Figure 2 Trends for syphilis co-infection in HIV seroconverters from Germany, 1996-2007. Proportions 
of HIV seroconverters with probable coincident syphilis, and syphilis infection preceding HIV infection, 
from 1996-2007 (with 95% CI). The declining proportion of HIV seroconverters with coincident syphilis 
after 2003 reflects the course of the epidemic in Berlin (see supplemental online figure 3). The 




Table 1 Time trends for syphilis co-infection and other potentially confounding parameters in the 










Table 2 Results of Poisson regression for interaction of time dependent parameters (1996-2004) with 




*How to read prevalence ratios: syphilis antibody prevalence rate increased by 19.0% per year; 
seroconverters from Berlin had a 84.9% higher prevalence compared to other seroconverters; for each 
year of age the prevalence of a preceding syphilis infection increased by 2.9%. 
  
